Added to YB: 2026-01-16
Pitch date: 2026-01-14
TENX [bullish]
Tenax Therapeutics, Inc.
-12.97%
current return
Author Info
No bio for this author
Company Info
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Market Cap
$610.6M
Pitch Price
$18.27
Price Target
201.00 (+1000%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-13.22
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Tenax Therapeutics: Life-Altering Anecdotes, Real Phase 3 Risk, and Enormous Upside
TENX (BioPick selection): Oral levosimendan targeting 1.4M PH-HFpEF patients (no approved drugs). P2 hit 6MWT endpoint but measured at drug trough w/ IV formulation. P3 uses oral TID dosing for better exposure. KOLs report 'outrageous' patient improvements. Q3 readout. 500-1000% upside potential vs ~90% downside risk. PoS <50% but massive upside skew makes current valuation attractive.
Read full article (11 min)